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Abstract
Background: Non alcoholic fatty liver disease (NAFL) consists in the accumulation of fat vacuoles
in the cytoplasm of hepatocytes. Many etiologic factors are associated with NAFL, such as, the
metabolic syndrome factors, medications, bariatric surgery, nutritional disorders. However, very
little information is available on the clinical relevance of this disorder as a health problem in the
general population.
Methods and design: The aim of the study is establish the risk factors most frequently associated
with NAFL in a general adult population assigned to the primary care units and to investigate the
relationship between each component of the metabolic syndrome and the risk of having a NAFL.
A population based case-control, observational and multicenter study will be carried out in 18
primary care units from the "Area de Gestión del Barcelonés Nord y Maresme" (Barcelona)
attending a population of 360,000 inhabitants and will include 326 cases and 370 controls. Cases
are defined as all subjects fulfilling the inclusion criteria and with evidence of fatty liver in an
abdominal ultrasonography performed for any reason. One control will be randomly selected for
Published: 3 October 2008
BMC Gastroenterology 2008, 8:44 doi:10.1186/1471-230X-8-44
Received: 4 September 2008
Accepted: 3 October 2008
This article is available from: http://www.biomedcentral.com/1471-230X/8/44
© 2008 Caballería et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Gastroenterology 2008, 8:44 http://www.biomedcentral.com/1471-230X/8/44
Page 2 of 6
(page number not for citation purposes)
each case from the population, matched for age, gender and primary care center. Controls with
fatty liver or other liver diseases will be excluded.
All cases and controls will be asked about previous hepatic diseases, consumption of alcohol,
smoking and drugs, and a physical examination, biochemical analyses including liver function tests,
the different components of the metabolic syndrome and the HAIR score will also be performed.
Paired controls will also undergo an abdominal ultrasonography.
Discussion: This study will attempt to determine the factors most frequently associated with the
presence of NAFL investigate the relationship between the metabolic syndrome and the risk of
fatty liver and study the influence of the different primary care professionals in avoiding the
evolution of the disease.
Background
Non alcoholic fatty liver disease (NAFL) consists in the
accumulation of fat vacuoles in the cytoplasm of hepato-
cytes and is characterized by the presentation of hepatic
lesions similar to those made by alcohol in subjects with-
out significant alcohol consumption. This term was intro-
duced by Ludwig J in 1980 [1] and covers a wide spectrum
of hepatic lesions including simple fatty liver, steatohepa-
titis with necroinflammatory changes and a variable
degree of fibrosis which may finally progress to liver cir-
rhosis and, even hepatocarcinoma. However, there is little
information on the clinical relevance of this disorder as a
healthcare problem in the general population, since the
studies published generally include a limited number of
patients and the diagnosis is established on the basis of
clear biochemical alterations and liver biopsy [2].
Many etiologic factors are associated with NAFL and are
classified as primary, related to factors that cause an
increase in insulin resistance (obesity, diabetes, dysli-
pemia), and the metabolic syndrome (obesity, type 2 dia-
betes, dyslipemia and arterial hypertension) and
secondary to consumption of medications (amiodarone,
tamoxifen, corticoids, estrogenos, nifedipine) to meta-
bolic congenital or acquired alterations, nutrition, surgi-
cal procedures, and other toxics [3-7]. In clinical practice
most patients with NAFL have obesity, type 2 diabetes or
dyslipemia as the etiologic factor, with the association of
several of these factors being frequent [8].
NAFL is possibly the most common cause of an elevation
in transaminases in adults [9] and is considered the
hepatic component of the metabolic syndrome [3]. The
importance to detect patients with NAFL is to intervene in
the associated factors and avoid evolution to more severe
forms of the disease.
Fatty liver is an ever more prevalent disease involving 17
to 33% of the general population according to the differ-
ent series and is increasing with the higher incidence of
obesity [10]. A currently ongoing study in our reference
area has found a prevalence of NAFL about 23% – 25%
correlated with components of the metabolic syndrome,
similar to other series [11]. In this study, the most impor-
tant risk factor for NAFL is obesity, with 70% of over-
weight or obese patients presenting this disease.
Most patients with NAFL are asymptomatic. Diagnosis is
made by presentation of increased transaminases, espe-
cially ALT, found during a health check up or during the
study of some other manifestation of the metabolic syn-
drome. Diagnosis may also be suspected by accidental dis-
covery of hepatomegaly or a radiological test carried out
for another reason showing suggestive changes of fatty
liver [8], although the final diagnosis should be con-
firmed by liver biopsy.
As we have seen the main risk factor for the development
of NAFL is, therefore, obesity. It is well known that the
increase in the number of obese persons within the gen-
eral population has progressed up to the point that the
healthcare authorities consider obesity to be one of the
main healthcare problems for the near future and it has
been made one of the priorities for intervention and
investigation. In addition, patients with NAFL who are
overweight/or obese are more to likely to develop steato-
hepatitis, with a percentage of these patients evolving to
more severe forms of liver disease. We therefore believe
that it is important to determine several indexes with the
aim to establish which patients may evolve to more severe
forms. These indexes are the HAIR score established by
Dixon [12], the Mayo Clinic index (NAFLD fibrosis score)
[13], among others. The HAIR score includes: insulin
resistance defined as: type 2 diabetes with baseline glycae-
mia values greater than 110 mg/dl and less than 126 mg/
dl and two of the following factors: arterial hypertension,
triglycerides above 150 mg/dl and/or HDLc < 35 in males
and < 39 in females, a waist/hip index > 0.90 in males and
0.85 in females and/or body mass index >30 kg/m2, and
ALT levels > 40. Patients with a HAIR score ≥ 2 are consid-
ered to have a high probability of developing non alco-
holic steatohepatitis.BMC Gastroenterology 2008, 8:44 http://www.biomedcentral.com/1471-230X/8/44
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The NAFLD fibrosis score combines: age, hyperglycaemia,
body mass index, platelet count, albumin values and the
AST/ALT ratio. The regression formula (risk score) for pre-
diction of severity of fibrosis based on these 6 variables is:
NAFL fibrosis score = -1.675 + 0.037 × age (years) + 0.094
× BMI (kg/m2) +1.13 × IFG/diabetes (yes = 1, no = 0) +
0.99 × AST/ALT ratio – 0.013 × platelet (×109/l) – 0.66 ×
albumin (g/dl). Using the area under the ROC curve, 2
cutoff points were selected to identify the presence
(greater than 0.676) and absence (lower than – 1.455) of
significant fibrosis.
In addition to knowing the risk factors associated with the
presence of NAFL, it is important to know the relationship
between NAFL and the metabolic syndrome. The presence
of the metabolic syndrome is increasing in the last years
and is constituted by the presence of several factors in a
same subject such as obesity, arterial hypertension, dysli-
pemia and glycaemia intolerance. Some criteria define the
metabolic syndrome with the most commonly used being
those of the World Health Organization (WHO) [14]
modified by the European Group for the Study of Insulin
Resistance (EGIR) [15], the criteria of the Adult Treatment
Panel III (ATP-III) of the National Cholesterol Education
Program (NCEP) [16], and those of the International Fed-
eration Diabetes [17]. These criteria include a combina-
tion of clinical and analytical parameters, mainly
abdominal perimeter. Other parameters are the body
mass index, insulin levels, arterial hypertension, glycae-
mia, HDL, triglycerides and microalbuminuria. So, the
criteria of the WHO require the presentation of some
alteration in carbohydrate metabolism, whether diabetes,
abnormal glucose tolerance or resistance to insulin and
two of the following criteria must also be taken into
account: arterial hypertension > 140/90 mmHg, obesity
(BMI = 30 kg/m2), hypertriglyceridemia ≥ 150 mg/dL or
cHDL values < 35 in males and < 40 in females and micro-
albuminuria ≥ 20 μg/min. The EGIR has proposed several
changes in the definition of the WHO, such as the pres-
ence of obesity (waist perimeter ≥ 94 cm in males and ≥
80 cm in females), fasting plasma insulin determination
and altered fasting glycaemia. The criteria of ATP-III of the
NCEP are based on the presence of abdominal obesity (≥
102 cm in males and ≥ 88 cm in females), hypertriclycer-
idemia (≥ 150 mg/dL), cHDL values < 40 mg/dl in males
and < 50 mg/dl in females, arterial hypertension (≥ 130/
85 mmHg) and altered fasting glycaemia (≥ 110 mg/dL).
Finally, the criteria of the International Federation of Dia-
betes are based on the presence of abdominal obesity (≥
94 cm in males and ≥ 80 cm in females), arterial hyperten-
sion (≥ 130/85 mmHg), altered fasting glycaemia (≥ 100
mg/dL), cHDL values (<40 mg/dl in males and <50 mg/dl
in females), and hypertriclyceridemia (≥ 150 mg/dL).
Given the importance of the metabolic syndrome we will
analyse these three types of criteria in all the study subjects
to determine which criteria identify the metabolic syn-
drome best.
Objectives
Main objectives
1. Establish the factors most frequently associated with
the presence of NAFL in the people attending primary
healthcare centers in the North Barcelona and Maresme
area.
2. Evaluate the influence of each of the components mak-
ing up the metabolic syndrome and the risk of having
NAFL.
3. Identify the subjects who may progress to chronicity
and the factors favouring progression.
Secondary objective
1. Identify a cohort of patients with fatty liver with no evi-
dence of previous liver disease to perform a prospective
follow-up.
Methods and design
We will carry out a observational analytical, population-
based, multicentre study of cases and controls attending
primary healthcare centers in the North Barcelona and
Maresme area. The study has been approved by the Ethical
Committee of Clinical Investigation, Jordi Gol i Gurina
Foundation.
Study subjects
This will be a multicentre study including the participa-
tion of 18 primary care teams covering a population of
360,000 inhabitants of an urban, and semi-rural zone of
North Barcelona and Maresme, Spain.
Definition of cases
All adult patients fulfilling inclusion criteria in whom
fatty liver is detected by means of ultrasonography per-
formed for any reason in the reference Department of
Radiology at the beginning of the study and have not
received previous treatment for NAFL. Subjects will be
considered as cases if they present fatty liver defined
according to the standard criteria accepted by the Ameri-
can Gastroenterology Association: An Increase in hepatic
echogenicity taking renal echogenicity as a reference, the
presence of enhancement and lack of differentiation in
periportal intensity and the vesicular wall due to great
hyperechogenicity of the parenchyma. The degree of
involvement will be standardized with a semiquantitative
scale of the degree of hepatic enhancement.
Definition of controls
For every case an age (± 5 years) and sex-matched control
will be selected from the same primary care centre by theBMC Gastroenterology 2008, 8:44 http://www.biomedcentral.com/1471-230X/8/44
Page 4 of 6
(page number not for citation purposes)
same health care team. The controls will be selected from
the SIAP (Primary Care Information System), a database
that collects all the people that belong to one primary care
center. This database in more complete and more updated
than the population census. The controls will be invited to
voluntarily participate and informed consent will be
obtained for performing ultrasonography and analytical
tests to ensure the absence of manifest hepatic disease.
Subjects with normal ultrasonography results without
alterations of hepatic enhancement will be considered as
controls.
Inclusion criteria
Adults of both sexes from these Primary Care teams
between the age 15 and 80 years who wish to voluntarily
participate in the study and who have signed a written
informed consent form to participate.
Exclusion criteria
Alcohol intake > 30 g/day in males and > 20 g/day in
females. Presence of chronic liver disease. Presence of the
hepatitis B virus surface antigen or the presence of virus
hepatitis C antibodies. Subjects with conditions or dis-
eases hindering data collection and follow up of the study
such as incapacitating diseases, cognitive deterioration,
institutionalized patients or subjects with no fixed address
in any of the basic areas of the study. Subjects who do not
provide written informed consent to participate in the
study. The cases and controls with any exclusion criteria in
their clinical history will not be invited to participate.
Sample size
The prevalence of risk factors, except for alcohol, pre-
sented in the Spanish population in association with the
presence of fatty liver described in the literature is the fol-
lowing: obesity 17.0%, diabetic mellitus 10.9%, and dys-
lipemia 18%. For a contrast of bilateral hypothesis and to
detect an odds ratio of a minimum of 1.8 with exposure
to one certain risk factor in the control group of at least
10%, with a alfa risk of 0.05 and a statistical power of
80%, 296 cases and 296 controls will be necessary. If we
assume that 15% of the controls will have NAFL (not
reflected in the clinical history) and that 10% of the cases
and controls will have a high alcohol intake or the pres-
ence of hepatitis C virus antibodies or chronic liver dis-
ease (not reflected in the clinical history), 326 cases and
370 controls will be necessary.
Variables
The following covariables will be evaluated in the patients
fulfilling the inclusion criteria and who accept to partici-
pate in the study.
1. Sociodemographic variables: Age, sex, occupation, edu-
cation and place of residence.
2. Clinical history including:
2.1. Personal history of liver disease, biliary lithiasis, sur-
gical interventions.
2.2. Presence of comorbidities: Obesity and being over-
weight, type 2 diabetes, dyslipemia and arterial hyperten-
sion.
2.3. Alcohol intake: We will determine the type and quan-
tity of alcoholic beverages consumed. The beverages con-
sumed will be calculated per unit of standard beverage
(glasses), differentiating the consumption between work-
ing days and the weekend. This will allow the calculation
of the unit of standard beverage for each patient. Further-
more, the personal history of each case will be reviewed to
rule out the possible history of high beverage consump-
tion.
2.4. Smoking habit.
2.5. Habitual drug use: history of drug use during previous
six months.
3. Physical examination:
3.1. Anthropometric data: weight, height, abdominal
obesity and body mass index. The measurement of
abdominal obesity will be done through the determina-
tion of the waist and hip circumferences using a tape
measure (waist circumference will be considered the inter-
mediate abdominal area perimeter between the last costal
arch and the iliac crest measured in the horizontal plane,
and hip circumference as that obtained in the plane of
maximum relief of the gluteus muscles). The body mass
index will be calculated according to the classical weight
formula (kg/height m2).
3.2. Determination of arterial pressure: This will be deter-
mined with a validated automatic tensitometer with the
subject resting. Three determinations will be carried out,
separated by two minutes, and the final arterial pressure
will be the average of the last two determinations discard-
ing the first reading.
4. Analytical determinations:
4.1. Blood analyses will include: a complete haemogram,
glycaemia, glycosylated haemoglobyn, urea, creatinine,
uric acid, a lipid study (cholesterol, triglycerides, HDL,
LDL), and liver function tests, including hepatitis markers
(hepatitis B surface antigen virus and hepatitis C virus
antibodies).BMC Gastroenterology 2008, 8:44 http://www.biomedcentral.com/1471-230X/8/44
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4.2. Baseline insulin levels will be determined by the
immunochemoluminescence method.
4.3. Determination of insulin resistance will be estab-
lished with the HOMA method (homeostasis model
assessment). ([glycaemia (mmol/L) x insulin (mU/L)]/
22.5).
4.4. A sample of the first urine in the morning will be
taken to determine microalbuminuria.
4.5. Special analytical determinations: Frozen serum from
all patients will be kept to determine different fibrotic
markers (hyaluronic acid, leptin, adiponectin, TNF-alfa).
5. Determination of the different fibrotic indexes (HAIR
score [12], NAFLD fibrosis score [13]).
6. Diagnosis of the metabolic syndrome: This will be
made according to the criteria of the WHO modified by
the European Group for the Study of Insulin Resistance
(EGIR)[15], the Adult Treatment Panel III (ATP-III) of the
National Cholesterol Education Program (NCEP) [16]
and the International Federation of Diabetes [17].
Control group
All the patients in this group will undergo ultrasonogra-
phy for ruling out the presence of fatty liver.
Plan of analysis
Data will be introduced into an ACCESS database and
then analysed.
A descriptive univariate and bivariate statistical analysis
will be performed, analysing the qualitative variables with
the chi-square test and the quantitative variables with the
Students-t test. Statistical significance will be established
at 5% for all the bivariate analyses and contrasts will be
considered at a bilateral level. Bivariate and multivariate
analysis will be performed by means of a logistic regres-
sion model to observe the association of hypothetical risk
factors of NAFL by calculating the odds ratio for each of
these factors.
Discussion
NAFL is a very prevalent disease and the present study will
provide knowledge as to the most frequently associated
factors in our reference area as well as the association
between these factors and the presence of the metabolic
syndrome, the prevalence of which is very high in Western
countries. This will therefore provide appropriate data of
our reference population regarding this increasingly more
prevalent disease to sensitize healthcare professionals of
the importance of the same and to insist about the risk fac-
tors, through norms of behavior, diet and drugs from our
primary care centers to avoid the progression of NAFL to
chronicity. Moreover, the study itself will generate a
cohort of patients which, in successive years, will contrib-
ute knowledge regarding the natural history of NAFL.
On the other hand, health checkups are increasingly more
common in the population as is the accessibility to both
analytical and radiological diagnostic tests making it eas-
ier to detect these cases and consequently intervene. More-
over, in our country the diagnosis of NAFL is increasingly
more frequent due to the interest given to this disease and,
as has been mentioned, to the higher prevalence of obes-
ity, manifesting during adolescence. Thus, although in the
past NAFL was considered to be a disease mainly affecting
the middle-aged, obese, and, in many cases, diabetic
women, it has currently been shown to affect both sexes
equally after adolescence [18].
The limitations of the studies of cases and controls are
related to the representativeness of the cases selected for
the study with respect to the whole population of cases.
We can not make a random selection of the cases because,
a priori, we do not know who this population is. With the
design of this study we propose to select the cases in which
a hepatic ultrasonography has been performed in the
Radiology Department of reference in Primary Care of the
population to study. This will ensure the origin of the
populational basis of the cases and the accessibility to the
main definitive diagnostic proof of the case. Cases which
are not suspected, not diagnosed or who do not consult in
the primary care may be under-represented but this possi-
ble selection bias will not be systematically introduced.
Another limitation of the study is related to the use of
hepatic ultrasonography for the diagnosis of fatty liver.
The gold standard for diagnosis of this disease is liver
biopsy. Nonetheless, studies comparing the diagnostic
utility of ultrasonography compared with liver biopsy
have shown a sensitivity of greater than 90% and a specif-
icity of greater than 80% for ultrasonography in detecting
the presence of fatty liver. The main limitation seems to be
the difficulty in detecting the presence of fatty liver when
the infiltration is of less than 30% of the hepatic content.
Another limitation of ultrasonography is the lack of infor-
mation regarding the histologic changes associated with
disease progression. To achieve this liver biopsy would be
required which, in our case would be referred to the refer-
ence hospital on both clinical and biochemical suspicion
of progression. Therefore, ultrasonography of the liver is
currently the test of reference for the detection of fatty liver
at a population level [19].
Non alcoholic fatty liver disease is a health problem
which, in association with other frequent conditions, is
very prevalent in our centres. Although until recently thePublish with BioMed Central    and   every 
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presence of this disease was approached as a minor prob-
lem, it must be taken into account that it may be poten-
tially serious because of its possible evolution to
chronicity and to hepatic cirrhosis. On the other hand, its
detection today in primary care centers is relatively easy
and accessible, and more importantly, a multifactorial
intervention on the risk factors may favour its remission
and thereby avoid the appearance of more severe hepatic
complications.
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